This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (105) CIHR funded proposals with peer-review reports (Canada) (28)

Published on in Vol 6, No 8 (2017): August

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Authors of this article:

Ian Gilron 1 Author Orcid Image ;   Dongsheng Tu 2 Author Orcid Image ;   Ronald Holden 2 Author Orcid Image ;   Tanveer Towheed 2 Author Orcid Image ;   Elizabeth Vandenkerkhof 2 Author Orcid Image ;   Roumen Milev 2 Author Orcid Image
Article Authors Cited by (1) Tweetations (3) Metrics
Ian Gilron 1, MSc, MD;  Dongsheng Tu 2, PhD;  Ronald Holden 2, PhD;  Tanveer Towheed 2, MD;  Elizabeth Vandenkerkhof 2, DrPH;  Roumen Milev 2, MD, PhD

1 Queen's University, Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston, ON, CA

2 Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute , Kingston, ON, CA

Corresponding Author:

  • Ian Gilron, MSc, MD
  • Queen's University
  • Department of Anesthesiology and Perioperative Medicine
  • Queen's University
  • Kingston General Hospital
  • 76 Stuart Street, Victory 2 Pavillion
  • Kingston, ON
  • CA
  • Phone: 1 613 549 6666 ext 3963
  • Email: gilroni@queensu.ca